PHASE-II TRIAL OF DOXORUBICIN THERAPY FOR ADVANCED ISLET CELL-CARCINOMA

  • 1 January 1982
    • journal article
    • research article
    • Vol. 66  (7) , 1567-1569
Abstract
Twenty evaluable patients with advanced islet cell carcinoma were treated with doxorubicin at a dosage of 60 mg/m2 every 3-4 wk. Toxicity was clinically tolerable and characteristic of doxorubicin therapy. Although all patients had previously been treated with other chemotherapy regimens, 4 (20%) had objective therapeutic responses persisting for 2-30.5 mo. Doxorubicin has definite therapeutic activity in islet cell carcinoma and is currently being evaluated in combination chemotherapy regimens.

This publication has 1 reference indexed in Scilit: